This study is being done to test whether the oral (by mouth) drug, regorafenib, is effective in reducing the risk of colon cancer recurring after patients have received standard chemotherapy (called adjuvant chemotherapy).
The main purpose of this study is to compare the effects (good and bad) of regorafenib to placebo when given to patients with high-risk colorectal cancer after they have completed adjuvant chemotherapy.
Regorafenib is an oral targeted therapy for cancer. A targeted therapy stops cancer cells from growing by targeting and blocking proteins that help cancer cells grow. Regorafenib is approved by the U.S. Food and Drug Administration (FDA) for use in treating colorectal cancer that has metastasized (spread) beyond the colon and nearby lymph nodes to other parts of the body. Regorafenib is considered investigational in this study because it has not been approved by the FDA for use in patients with colon cancer that has not metastasized (early-stage colon cancer).
Placebo, for this study, is a tablet that looks like regorafenib but contains no medication.